摘要
[目的]观察和评价培美曲塞联合卡铂一线治疗晚期非小细胞肺癌的疗效和不良反应。[方法]将收集的29例晚期非小细胞肺癌患者采用培美曲塞联合卡铂(PC方案)作为一线化疗方案。2个周期化疗后进行疗效、不良反应评价。[结果]患者的近期有效率、中位无进展生存期(PFS)、中位生存期及1年生存率分别为44.8%、6.3个月、10.1个月及45.8%。主要不良反应是骨髓抑制、脱发、皮疹及消化道反应,但均可以耐受。[结论]培美曲塞联合卡铂(PC方案)一线治疗晚期非小细胞肺癌有较好的近期疗效,不良反应可耐受。
[ Purpose] To investigate the efficaey and side effects of pemetrexed combined with earboplatin in the first-line treatment for advanced non-small cell lung cancer. [Methods] Twenty-nine patients with advanced non-small cell lung cancer were enrolled and treated with pemetrexed plus carboplatiu （PC regimen）. The efficacy and side effects were evaluated after 2 cycles of chemotherapy. [Resultsl The response rate, progress-free-survival（PFS）, median survival time（MST） and l-year survival rate were 44.8%, 6.3 months, 10.1 months and 45.8%, respeetively. The main side eftbcts were bone marrow suppression, alopecia, skin eruption and gastrointestinal toxicity, but they were tolerable. [Conclusion] Pemetrexed plus carboplatin in the first-liue treatment for advanced non-small cell lung cancer is effective, sate and tolerable.
出处
《中国肿瘤》
CAS
2013年第3期235-237,共3页
China Cancer
关键词
培美曲塞
卡铂
非小细胞肺癌
化疗
pemetrexed
carboplatin
non-small cell lung cancer
chemotherapy
